Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Structure/function reg

This article was originally published in The Tan Sheet

Executive Summary

Proposed agency guidance providing examples of supplement labeling claims that would or would not be deemed disease claims is unnecessary, CHPA, CRN, AHPA, NNFA assert in separate comments. Trade associations say Jan. 6, 2000 final reg's lengthy preamble and numerous "courtesy" letters issued by FDA provide adequate industry guidance. Remarks respond to FDA's request for comments by May 23 on development of proposed guidance (1"The Tan Sheet" Feb. 26, p. 23)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel